| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 12 | 2023 |
| 1169P Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment ME Vázquez-Cruz, C Molina-Aguilar, P Basurto-Lozada, HM Said, ... Annals of Oncology 34, S695-S696, 2023 | | 2023 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 21 | 2023 |
| Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, ... The lancet respiratory medicine 10 (9), 888-899, 2022 | 91 | 2022 |
| 772P Discovery and exploration of a live bacterial consortium as co-therapy to enhance immune checkpoint inhibitor response in melanoma patients MJ Robinson, K Vervier, S Harris, A Popple, D Klisko, R Hudson, ... Annals of Oncology 33, S894, 2022 | | 2022 |
| Transferring molecular level changes to bulk properties via tunable self-assembly and hierarchical ordering L Thomson, D McDowall, L Marshall, O Marshall, H Ng, J Homer, ... | 1 | 2022 |
| Spinal radiographic progression and predictors of progression in patients with radiographic axial spondyloarthritis receiving ixekizumab over 2 years D van der Heijde, M Østergaard, JD Reveille, X Baraliakos, A Kronbergs, ... The Journal of Rheumatology 49 (3), 265-273, 2022 | 23 | 2022 |
| Acknowledgment to Reviewers of Membranes in 2021 A Abdala, K Ali, H Abdo, SA Ali, MA Abdul-Hamid, A Aliyu, R Abdur, ... Membranes 12, 155, 2022 | | 2022 |
| Using small angle scattering to understand low molecular weight gels D McDowall, DJ Adams, AM Seddon Soft Matter 18 (8), 1577-1590, 2022 | 28 | 2022 |
| Poursuite ou arrêt du traitement par l’ixékizumab chez des patients atteints de spondyloarthrite axiale et ayant atteint la rémission: résultats d’une étude de retrait … R Landewé, L Gensler, D Poddubnyy, P Rahman, M Hojnik, X Li, ... Revue du Rhumatisme 88, A108-A109, 2021 | | 2021 |
| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 676 | 2021 |
| Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials MC Genovese, E Mysler, T Tomita, KA Papp, C Salvarani, S Schwartzman, ... Rheumatology 60 (11), 5485-5485, 2021 | | 2021 |
| Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double‐blind withdrawal study LC Coates, SG Pillai, H Tahir, I Valter, V Chandran, H Kameda, M Okada, ... Arthritis & Rheumatology 73 (9), 1663-1672, 2021 | 19 | 2021 |
| Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled … RBM Landewé, LS Gensler, D Poddubnyy, P Rahman, M Hojnik, X Li, ... Annals of the rheumatic diseases 80 (8), 1022-1030, 2021 | 37 | 2021 |
| POS0918 evaluation of spinal radiographic progression in patients with radiographic axial spondyloarthritis receiving ixekizumab therapy over 2 years D Van der Heijde, M Østergaard, JD Reveille, X Baraliakos, A Kronbergs, ... Annals of the Rheumatic Diseases 80 (Suppl 1), 720-720, 2021 | 5 | 2021 |
| POS0912 Long-term treatment with ixekizumab in patients with axial spondyloarthritis: two-year results from COAST-Y J Braun, U Kiltz, A Deodhar, T Tomita, M Dougados, R Bolce, D Sandoval, ... Annals of the Rheumatic Diseases 80 (Suppl 1), 716-717, 2021 | 2 | 2021 |
| Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study. PG Corrie, SJ Welsh, GD Stewart, G Doherty, K Vervier, A Neville, ... Journal of Clinical Oncology 39 (15_suppl), TPS2665-TPS2665, 2021 | | 2021 |
| Efficacy and safety of baricitinib in patients with COVID-19 infection: results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... MedRxiv, 2021.04. 30.21255934, 2021 | 22 | 2021 |
| P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis X Baraliakos, R Bolce, DS Calderon, SL Leage, V Geneus, D Adams, ... Rheumatology 60 (Supplement_1), keab247. 188, 2021 | | 2021 |
| Outstanding Reviewers for Soft Matter in 2020 D Adams, G Baeza, J Conrad, P Kosovan, R Metzler, S Pispas, K Schultz, ... Soft Matter 17 (5455), 5455, 2021 | | 2021 |
